{"id":"il-23-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL6042642","moleculeType":null,"molecularWeight":"381.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-23 is a key cytokine that drives Th17 cell differentiation and maintains inflammatory responses in autoimmune and inflammatory diseases. By blocking IL-23 or its receptor, this therapy reduces the expansion and activation of pro-inflammatory T cells, thereby suppressing disease-driving immune responses. This mechanism has shown efficacy in conditions characterized by IL-23-mediated inflammation, particularly in skin and gut-associated diseases.","oneSentence":"IL-23 therapy inhibits the IL-23 signaling pathway to reduce pathogenic T-cell responses and inflammatory cytokine production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:32.679Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis"},{"name":"Inflammatory bowel disease (Crohn's disease and ulcerative colitis)"},{"name":"Psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT07234838","phase":"","title":"Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)","status":"RECRUITING","sponsor":"Jonathan Krygier","startDate":"2026-02-01","conditions":"Psoriasis, Condyloma Acuminata, Biotherapies","enrollment":600},{"nctId":"NCT04340076","phase":"PHASE4","title":"Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2020-08-20","conditions":"Psoriasis, Psoriasis Vulgaris","enrollment":244},{"nctId":"NCT07448402","phase":"","title":"Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease","status":"NOT_YET_RECRUITING","sponsor":"Caja Costarricense de Seguro Social","startDate":"2026-05","conditions":"Psoriasis, Psoriasis Arthritis, Psoriasis (PsO)","enrollment":50},{"nctId":"NCT06563323","phase":"PHASE2","title":"Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)","status":"RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2025-02-01","conditions":"Pyoderma Gangrenosum, Skin Diseases, Wound Heal","enrollment":17},{"nctId":"NCT06598943","phase":"PHASE2","title":"A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-10","conditions":"Ulcerative Colitis, Ulcerative Colitis Chronic","enrollment":140},{"nctId":"NCT07245394","phase":"","title":"Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)","status":"RECRUITING","sponsor":"TIDHI Innovation Inc.","startDate":"2026-01-29","conditions":"Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC)","enrollment":200},{"nctId":"NCT07336641","phase":"","title":"LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice","status":"NOT_YET_RECRUITING","sponsor":"Fondazione ISIDE","startDate":"2026-01","conditions":"Psoriasis, Atopic Dermatitis, Vitiligo","enrollment":20000},{"nctId":"NCT04572815","phase":"PHASE2","title":"Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-05-14","conditions":"Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm","enrollment":116},{"nctId":"NCT03167437","phase":"PHASE1, PHASE2","title":"An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-10-30","conditions":"Crohn's Disease","enrollment":35},{"nctId":"NCT07216014","phase":"PHASE4","title":"Interleukin-23 Monoclonal Antibody for Inflammatory Bowel Disease: Efficacy and Safety","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-12-01","conditions":"Crohn's Disease and Ulcerative Colitis","enrollment":200},{"nctId":"NCT04271540","phase":"PHASE4","title":"MIcrovascular dysfuNction In Moderate-severe Psoriasis","status":"COMPLETED","sponsor":"Marcelo F. Di Carli, MD, FACC","startDate":"2020-04-04","conditions":"Psoriasis, Cardiovascular Disease","enrollment":36},{"nctId":"NCT06336343","phase":"PHASE4","title":"Bimekizumab in Plaque Psoriasis","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2024-06-03","conditions":"Plaque Psoriasis","enrollment":60},{"nctId":"NCT04630652","phase":"PHASE4","title":"Risankizumab Long-term Remission Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jaehwan Kim","startDate":"2021-04-07","conditions":"Psoriasis","enrollment":20},{"nctId":"NCT05283135","phase":"PHASE2","title":"High Dose Risankizumab for Psoriasis","status":"COMPLETED","sponsor":"Oregon Medical Research Center","startDate":"2022-03-01","conditions":"Psoriasis","enrollment":20},{"nctId":"NCT03524092","phase":"PHASE3","title":"A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-10-19","conditions":"Ulcerative Colitis","enrollment":1177},{"nctId":"NCT06274554","phase":"PHASE3","title":"Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2024-10-04","conditions":"Crohn's Disease, Inflammatory Bowel Diseases","enrollment":120},{"nctId":"NCT07184138","phase":"","title":"Real-World Study on the Safety and Effectiveness of IL-23 Inhibitors for Inflammatory Bowel Disease in China","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-10-01","conditions":"Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)","enrollment":178},{"nctId":"NCT07177118","phase":"PHASE3","title":"Risankizumab for Fibrostenotic Crohn's Disease Treatment","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-20","conditions":"Crohn Disease, Crohn Disease and Ulcerative Colitis","enrollment":260},{"nctId":"NCT02648581","phase":"PHASE2","title":"Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-14","conditions":"Behçet Disease","enrollment":16},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT07121920","phase":"NA","title":"Ex-vivo Confocal Imaging and Proteomic Profiling to Determine Treatment Response in Children With IBD","status":"NOT_YET_RECRUITING","sponsor":"Cook Children's Health Care System","startDate":"2025-09-01","conditions":"IBD (Inflammatory Bowel Disease), IBD, IBD - Inflammatory Bowel Disease","enrollment":40},{"nctId":"NCT03358693","phase":"","title":"Molecular Signatures in Inflammatory Skin Disease","status":"RECRUITING","sponsor":"Prof. Dr. Stephan Weidinger","startDate":"2017-01-20","conditions":"Atopic Dermatitis, Psoriasis","enrollment":300},{"nctId":"NCT07041112","phase":"","title":"Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors","status":"COMPLETED","sponsor":"Juan Ruano Ruiz","startDate":"2012-01-01","conditions":"Psoriasis, Psoriatic Arthritis (PsA), Cardiovascular Risk Factors","enrollment":1000},{"nctId":"NCT06488170","phase":"","title":"A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting","status":"ACTIVE_NOT_RECRUITING","sponsor":"Almirall, S.A.","startDate":"2024-04-04","conditions":"Plaque Psoriasis","enrollment":42},{"nctId":"NCT05928039","phase":"PHASE4","title":"PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2023-10-25","conditions":"Crohn Disease","enrollment":297},{"nctId":"NCT06399432","phase":"NA","title":"Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors","status":"RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2022-10-18","conditions":"Psoriasis","enrollment":36},{"nctId":"NCT05111210","phase":"","title":"Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis","status":"RECRUITING","sponsor":"Institut Pasteur","startDate":"2021-12-14","conditions":"Psoriasis","enrollment":90},{"nctId":"NCT04823247","phase":"","title":"Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2021-11-22","conditions":"Plaque Psoriasis","enrollment":782},{"nctId":"NCT03465696","phase":"NA","title":"A Priming Intervention to Increase Patient Willingness to Use Injectables for the Management of Psoriasis","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-05-14","conditions":"Psoriasis","enrollment":180},{"nctId":"NCT06089590","phase":"","title":"Ibd CAncer and seRious Infections in France (I-CARE 2)","status":"RECRUITING","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2024-01-25","conditions":"IBD, Ulcerative Colitis, Crohn Disease","enrollment":6000},{"nctId":"NCT04505410","phase":"PHASE3","title":"Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"University of Miami","startDate":"2020-09-18","conditions":"Ulcerative Colitis","enrollment":32},{"nctId":"NCT01369355","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-09-13","conditions":"Crohn's Disease, Colitis, IBD","enrollment":1282},{"nctId":"NCT06792487","phase":"","title":"Immune Infiltrate Analysis of Psoriasis Skin During Therapy With Anti-interleukin 23 (IL-23)","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-09-04","conditions":"Psoriasis","enrollment":20},{"nctId":"NCT05290363","phase":"NA","title":"The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis","status":"RECRUITING","sponsor":"Institut Pasteur","startDate":"2022-10-06","conditions":"Spondyloarthritis","enrollment":90},{"nctId":"NCT06786507","phase":"","title":"A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis","status":"NOT_YET_RECRUITING","sponsor":"Helwan University","startDate":"2025-05-15","conditions":"Ulcerative Colitis (UC)","enrollment":100},{"nctId":"NCT03445845","phase":"PHASE4","title":"Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-12-14","conditions":"Axial Spondyloarthritis","enrollment":300},{"nctId":"NCT04971200","phase":"EARLY_PHASE1","title":"Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo","status":"COMPLETED","sponsor":"Premier Specialists, Australia","startDate":"2021-09-16","conditions":"Skin and Connective Tissue Diseases, Skin Diseases, Pigmentation Disorder","enrollment":12},{"nctId":"NCT06558305","phase":"","title":"IL-6, IL-12, IL-15 and IL-23 Expression Levels in Rheumatoid Arthritis Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-09","conditions":"Rheumatoid Arthritis","enrollment":80},{"nctId":"NCT04736966","phase":"PHASE1","title":"Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2021-03-03","conditions":"Alcoholic Liver Disease","enrollment":13},{"nctId":"NCT05110313","phase":"PHASE4","title":"Effects of Tildrakizumab on Epigenetic Age","status":"COMPLETED","sponsor":"Carlos Wambier","startDate":"2022-04-08","conditions":"Psoriasis, Aging, Epigenetic Disorder","enrollment":30},{"nctId":"NCT03975153","phase":"PHASE2","title":"Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2019-10-03","conditions":"Pityriasis Rubra Pilaris","enrollment":15},{"nctId":"NCT04541329","phase":"PHASE4","title":"Predicting Inflammatory Skin Disease Response to IL-23 Blockade","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-09-16","conditions":"Psoriasis Vulgaris","enrollment":7},{"nctId":"NCT03961815","phase":"PHASE3","title":"Open-label Extension Study of Brazikumab in Crohn's Disease","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2020-01-06","conditions":"Crohn's Disease, IBD","enrollment":18},{"nctId":"NCT06055699","phase":"","title":"Association Between the Occurrence of a Clinical RElapse and Gut MIcrobiota Modifications: a Cohort Study of Patients With pSOriasis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-03-01","conditions":"Psoriasis, Microbial Colonization","enrollment":50},{"nctId":"NCT04261010","phase":"NA","title":"TNF and IL23 Blocking Agents Gene Expression Ratios in the Psoriatic Arthritis Synovium_(TIGERS) Study","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2020-01-14","conditions":"Psoriatic Arthritis","enrollment":36},{"nctId":"NCT05390515","phase":"PHASE4","title":"Psoriatic Immune Response to Tildrakizumab","status":"UNKNOWN","sponsor":"University of California, San Francisco","startDate":"2022-09-01","conditions":"Psoriasis Vulgaris","enrollment":10},{"nctId":"NCT05957120","phase":"","title":"Subclinical Impairment of Cardiovascular System in Patients With Psoriasis","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2022-01-03","conditions":"Psoriasis, Inflammation, Endothelial Dysfunction","enrollment":100},{"nctId":"NCT04583956","phase":"PHASE2","title":"ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-10-23","conditions":"COVID-19","enrollment":214},{"nctId":"NCT03556202","phase":"PHASE3","title":"A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2018-09-03","conditions":"Psoriasis","enrollment":1936},{"nctId":"NCT05499416","phase":"PHASE4","title":"Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis","status":"WITHDRAWN","sponsor":"Innovaderm Research Inc.","startDate":"2023-01","conditions":"Psoriasis Vulgaris, Active Psoriatic Arthritis","enrollment":""},{"nctId":"NCT04096222","phase":"","title":"Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2021-06-29","conditions":"Pemphigus Vulgaris, Bullous Dermatoses, Autoimmune Diseases","enrollment":42},{"nctId":"NCT03690544","phase":"PHASE4","title":"Apremilast for RAS","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-10-12","conditions":"Recurrent Aphthous Stomatitis","enrollment":15},{"nctId":"NCT05386290","phase":"","title":"A Multicentered Prospective Cohort Study of Chinese IBD Patients","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-07-09","conditions":"Ulcerative Colitis, Crohn Disease","enrollment":200},{"nctId":"NCT02574637","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2016-01-05","conditions":"Crohn's Disease","enrollment":29},{"nctId":"NCT02955147","phase":"PHASE1, PHASE2","title":"Ustekinumab for the Treatment of Giant Cell Arteritis","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2016-12-01","conditions":"Giant Cell Arteritis, Temporal Arteritis, Horton's Disease","enrollment":13},{"nctId":"NCT04347473","phase":"PHASE4","title":"ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.","status":"RECRUITING","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2020-04-06","conditions":"Psoriasis","enrollment":25},{"nctId":"NCT03255382","phase":"PHASE3","title":"A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-08-22","conditions":"Psoriasis","enrollment":120},{"nctId":"NCT03828877","phase":"NA","title":"The Effect of Acupuncture on the Treatment of Endovenous Ablation on Pain, IL17 and IL 23","status":"COMPLETED","sponsor":"Kahramanmaras Sutcu Imam University","startDate":"2019-01-29","conditions":"Pain, Interleukin, Vessels; Varicose","enrollment":70},{"nctId":"NCT03385850","phase":"NA","title":"The Th17/Treg Cells and IL-23/IL-17 Axis and Early Enteral Nutrition in Sepsis","status":"COMPLETED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2017-10-01","conditions":"Sepsis, Immune System Disorder, Enteral Feeding","enrollment":53},{"nctId":"NCT01999868","phase":"PHASE2","title":"Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-03-19","conditions":"Psoriasis","enrollment":108},{"nctId":"NCT02031276","phase":"PHASE2","title":"Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-02","conditions":"Crohn Disease","enrollment":121},{"nctId":"NCT03565042","phase":"","title":"Mechanism of Action of Ustekinumab in Psoriatic Arthritis","status":"UNKNOWN","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2015-12-08","conditions":"Arthritis, Psoriatic","enrollment":16},{"nctId":"NCT03535233","phase":"PHASE4","title":"Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata","status":"COMPLETED","sponsor":"Cairo University","startDate":"2016-03","conditions":"Alopecia Areata","enrollment":40},{"nctId":"NCT00267969","phase":"PHASE3","title":"A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Centocor Research & Development, Inc.","startDate":"2005-12","conditions":"Psoriasis","enrollment":766},{"nctId":"NCT00771667","phase":"PHASE2","title":"A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2008-12","conditions":"Crohn's Disease","enrollment":526},{"nctId":"NCT00307437","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Centocor Research & Development, Inc.","startDate":"2005-05","conditions":"Psoriasis","enrollment":1230}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Risankizumab","Ustekinumab","Guselkumab"],"phase":"phase_3","status":"active","brandName":"IL-23 Therapy","genericName":"IL-23 Therapy","companyName":"Weill Medical College of Cornell University","companyId":"weill-medical-college-of-cornell-university","modality":"Biologic","firstApprovalDate":"","aiSummary":"IL-23 therapy inhibits the IL-23 signaling pathway to reduce pathogenic T-cell responses and inflammatory cytokine production. Used for Psoriasis, Inflammatory bowel disease (Crohn's disease and ulcerative colitis), Psoriatic arthritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}